Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALG-055009 in Healthy Volunteers and Subjects with Hyperlipidemia
NCT05090111Phase 1Completed
- Sponsor
- Aligos Therapeutics
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALG-055009 in hyperlipidemia (5 arms), sponsored by Aligos Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 35 days. Started Dec 2021; status: completed.
02
Drugs
ALG-055009
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT05090111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05090111.